53
Participants
Start Date
March 20, 2017
Primary Completion Date
July 21, 2020
Study Completion Date
November 5, 2020
AMV564
AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing
AMV564 in combination with pembrolizumab
AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
Weill Cornell Medical College, The New York Presbyterian Hospital, New York
New York Medical College, Hawthorne
University of Pennsylvania, Philadelphia
Johns Hopkins University, Baltimore
The Ohio State University Comprehensive Cancer Center, Columbus
Northwestern, Chicago
Washington University School of Medicine, St Louis
University of California, San Francisco, San Francisco
MD Anderson Cancer Center, The University of Texas, Houston
Fred Hutchinson Cancer Research, Seattle
Lead Sponsor
Amphivena Therapeutics, Inc.
INDUSTRY